Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas.
Nine women harboring uterine leiomyomas have been treated with subcutaneous injections and then with intranasal insufflation of luteinizing hormone-releasing hormone agonist for a total treatment period of 6 months. After initial stimulation, mean serum estradiol progressively decreased and stabilized at 36.8 +/- 4.9 pg/ml for the rest of the treatment period. The volume of uterine leiomyomas has been reduced by an average of 71%. Side effects and hot flushes were less severe and better tolerated than reported after sole subcutaneous administration.
D000281:Administration, Intranasal; D000328:Adult; D002064:Buserelin / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007889:Leiomyoma / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy; D013997:Time Factors; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy*
D002064:Buserelin